SCHEMBL4534205

SCHEMBL4534205

CC(C)c1ccccc1OC(C(=O)NO)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 2/20 0.45
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
KMT2A Q03164 3/20 0.43
MMP8 P22894 2/20 0.42
LPAR1 Q92633 1/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MMP9 P14780 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4534368 0.85 ALDH1A1 (0.50) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4533785 0.82 KMT2A (0.53) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4536701 0.82 MMP8 (0.48) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL8114258 0.79 MMP8 (0.43) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4526444 0.79 KMT2A (0.51) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4540199 0.79 ALDH1A1 (0.50) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4535628 0.78 KDM4E (0.44) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4561616 0.78 HDAC7 (0.46) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4536194 0.78 HDAC1 (0.46) HDAC7HDAC3HDAC4HDAC1HDAC2
SCHEMBL4535585 0.77 F9 (0.47) HDAC7HDAC3HDAC4HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
US-20090181943-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2009-07-16 US disclosed
WO-2008122115-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181943-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC11, HDAC3 HDAC7 7/4885HDAC3 3/4885HDAC4 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.